Abeona Therapeutics Inc. (NASDAQ: ABEO) stock gained by 14.71% at the last close whereas the ABEO stock price declines by 1.92% in the pre-market trading session. Abeona Therapeutics is a biopharmaceutical firm in the early stages of development that is working on gene and cell therapy for serious diseases.
On May 18, 2021, Abeona Therapeutics announced its first-quarter 2021 financial results. The summary is stated below:
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
- As of March 31, 2021, cash, cash assets, and short-term deposits calculated as $86.8 million, down from $95.0 million as of December 31, 2020. For the first quarter of 2021, the net capital used in financial operations was $13.6 million.
- In the first quarter of 2021, research and development (R&D) costs were $7.2 million, up from $6.8 million in the same timeframe in 2020. Raised clinical and development work for ABEO’s gene and cell therapy product candidates, as well as increased compensation and associated costs, drove up R&D expenses.
- In the first quarter of 2021, general and administrative (G&A) expenditures were $6.6 million, compared to $6.4 million in the same timeframe of 2020. G&A expenses rose largely as a result of higher professional fees, which were partly offset by lower salaries and related costs, as well as lower net other G&A expenses.
- The first quarter of 2021 saw a net loss of $16.0 million, compared to a net loss of $48.2 million in the same timeframe of 2020. The non-cash impairment fee of $32.9 million relating to the termination of the licensing arrangement with REGENXBIO in the first quarter of 2020 accounted for the majority of the reduction in a net loss.
Michael Amoroso, Chief Executive Officer of Abeona commented:
In 2021, ABEO is off to a flying start, owing to the laser-like emphasis on execution. ABEO is concentrating on finishing participation in the EB-101 Phase 3 pivotal VIITAL trial, determining a regulatory course for ABO-102 in MPS IIIA, delivering the first lot of Abeona-produced therapeutic grade ABO-102, and documenting additional neurocognitive and biomarker results from both the ABO-102 Transpher A and ABO-101 Transpher B trials. ABEO already has a strong preclinical pipeline, and they’re working on evaluating AAV capsids in order to start IND-enabling trials in two to three eye indications.